Merge Healthcare Has Seven New Contracts in January
Merge Healthcare announced that the company has started the year off with seven new contracts for its clinical trials solutions. These wins reflect continued momentum across all the clinical trials applications, and represent both new and expanded customer relationships.
In addition to the customizable myEDC platform, the Merge solution set for clinical trials includes applications for enterprise Electronic Data Capture (EDC), Interactive Voice and Web Response (IVR/IWR), electronic Patient Reported Outcomes (ePRO) via internet, phone or handheld device, and an endpoint adjudication module. The Merge CIMS platform for managing the imaging component of clinical trials was recently awarded Frost and Sullivan’s 2010 Healthcare Innovation for Medical Imaging Workflow Solutions of the Year. Merge capabilities extend across all stages of clinical trials, international studies, and many clinical specialty trials. The Merge suite of clinical trials solutions will be available for demonstration at the upcoming HIMSS conference February 20 – 24 in Orlando, Florida. Merge can be found at booth #3348.
“We’re thrilled with the recent momentum for this solution set,” said Jeff Surges, Merge CEO. “Clinical trials need efficient electronic workflow via an intuitive interface, and broad interoperability among associated applications, and imaging is a particular challenge. Just as with our iConnect platform for healthcare providers, Merge brings a new value proposition to these customers, and the recent wins show that the clinical trials market recognizes this.”
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
